NCT04378023Recruiting
Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Perihilar Cholangiocarcinoma. A Prospective Multicenter Study.
Source: ClinicalTrials.gov · Last updated 26 May 2026
Brief summary (registry, in English)
A prospective multicentre study which includes patients ≤ 70 years-old diagnosed of unresectable perihilar cholangiocarcinoma (pCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases. Liver transplantation preceded by neoadjuvant radiochemotherapy will be performed in this selected group. The primary endpoint will be overall survival at 1, 3, and 5 years post-transplant. The secondary endpoints will be: 1) recurrence-free survival at 1, 3 and 5 years post-transplant; 2) intention-to-treat survival of all patients included in the study at 1,3 and 5 years; 3) the rate of patients included in the study who are finally transplanted.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 34 (estimated)
- First submitted
- 4 May 2020
- Start date
- 24 Apr 2020
- Primary completion date
- 1 Jun 2027
- Lead sponsor
- Hospital Vall d'Hebron
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04378023
What you commit to
- Study type: Observational
- Planned participants: 34
- From 24 Apr 2020 to the primary completion date, 1 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those patients who have received chemotherapy or radiotherapy previously out of protocol
- Previous intent of surgical resection or percutaneous biopsy
- Previous or concurrent cancer that is different in primary site or histology from adenocarcinoma, except cervical carcinoma in situ, localized prostate cancer, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, T1). Any cancer curatively treated 5 years prior to entry is permitted.
Other illness
- Infection no controlled
Other
- Liver, extrahepatic or lymph node metastases
Who the study is looking for
- Willing and able to provide written consent form
- Age ≤ 70 years-old
- ECOG 0 or 1
- Unresectable hCCA ≤3cm in radial diameter
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of HPB Surgery and Transplants, Hospital Vall d´Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.